How have NWBO shares performed in 2024?

Northwest Biotherapeutics' stock was trading at $0.7010 at the beginning of the year. Since then, NWBO stock has decreased by 31.5% and is now trading at $0.48. View the best growth stocks for 2024 here .

When is Northwest Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our NWBO earnings forecast .

How were Northwest Biotherapeutics' earnings last quarter?

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) announced its earnings results on Tuesday, March, 5th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.45 million for the quarter.

What other stocks do shareholders of Northwest Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD) , Ocular Therapeutix (OCUL) , Melinta Therapeutics (MLNT) , (ZLTQ) (ZLTQ) , Avid Bioservices (CDMO) , Idera Pharmaceuticals (IDRA) , Amarin (AMRN) , Inovio Pharmaceuticals (INO) and MEI Pharma (MEIP) .

How do I buy shares of Northwest Biotherapeutics?

Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:NWBO

Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free NWBO Stock Alerts

$0.48

-0.03 (-5.88%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.48
▼
$0.52
50-Day Range: $0.48
▼
$0.61
52-Week Range: $0.40
▼
$1.09

Volume: 1.68 million shs
Average Volume: 1.59 million shs
Market Capitalization: $577.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines SEC Filings Short Interest

Get Northwest Biotherapeutics alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Northwest Biotherapeutics Stock (OTCMKTS:NWBO)

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

NWBO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NWBO Stock News Headlines

April 16, 2024 | americanbankingnews.com

Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Passes Below 200-Day Moving Average of $0.67

March 21, 2024 | prnewswire.com

Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors

April 20, 2024 | Banyan Hill Publishing (Ad)

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

March 2, 2024 | ft.com

‘Spoofing’ case might draw back curtain on high-speed trading firms

February 29, 2024 | uk.finance.yahoo.com

Northwest Biotherapeutics, Inc. (NWBO)

February 23, 2024 | benzinga.com

Northwest Biotherapeutics Stock (OTC:NWBO), Short Interest Report

February 7, 2024 | finance.yahoo.com

Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification

December 22, 2023 | msn.com

Northwest Biotherapeutics submits marketing application to UK MHRA for DCVax-L

April 20, 2024 | Banyan Hill Publishing (Ad)

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started

December 21, 2023 | finanznachrichten.de

Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For Glioblastoma

December 21, 2023 | finance.yahoo.com

Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma

November 22, 2023 | finance.yahoo.com

Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application

October 31, 2023 | morningstar.com

Northwest Biotherapeutics Inc NWBO

October 14, 2023 | msn.com

Northwest Bio: Another Small Filing Delay

October 13, 2023 | seekingalpha.com

NW Bio dips on announcing delay in submission of marketing application for DCVax

October 13, 2023 | marketwatch.com

Northwest Biotherapeutics Shares Slide on Application Delay

October 13, 2023 | finance.yahoo.com

Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application

September 12, 2023 | finance.yahoo.com

Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board

August 17, 2023 | msn.com

Northwest Bio: Is There Ever Going To Be A Right Time?

August 6, 2023 | usnews.com

Northwest Missouri State University

August 4, 2023 | health.usnews.com

Northwest Hospital

July 15, 2023 | thestreet.com

Why Northwest Bio Is Shunned by Savvy Health Care Investors

June 19, 2023 | pnj.com

Three rounds of severe weather expected over the next 24 hours for Northwest Florida

June 13, 2023 | health.usnews.com

HCA Houston Healthcare Northwest

May 27, 2023 | finance.yahoo.com

NWBO - Northwest Biotherapeutics, Inc.

May 9, 2023 | thestreet.com

Northwest Bio Warns FDA May Throw Out Phase III Brain Cancer Study

April 13, 2023 | health.usnews.com

Northwest Medical Center-Tucson

See More Headlines

Receive NWBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/05/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:NWBO
Previous Symbol: NASDAQ:NWBO
CUSIP: N/A
CIK: 1072379
Web: www.nwbio.com
Phone: (240) 497-9024
Fax: 240-627-4121
Employees: 25
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-62,600,000.00
Net Margins: -3,240.11%
Pretax Margin: -3,240.11%
Return on Equity: N/A
Return on Assets: -207.51%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.09
Quick Ratio: 0.09

Sales & Book Value

Annual Sales: $1.93 million
Price / Sales: 299.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.06) per share
Price / Book: -8.00

Miscellaneous

Outstanding Shares: 1,203,330,000
Free Float: 1,090,220,000
Market Cap: $577.60 million
Optionable: Not Optionable
Beta: -0.68

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Ms. Linda F. Powers J.D. (Age 68)
Chairperson, CEO, President, CFO & Chief Accounting Officer
Comp: $1.1M
Dr. Alton L. Boynton Ph.D. (Age 79)
Founder, Chief Scientific Officer, Secretary & Director
Comp: $450k
Dr. Marnix L. Bosch M.B.A. (Age 65)
Ph.D., Chief Technical Officer
Comp: $597.5k
Mr. Leslie J. Goldman (Age 79)
Senior VP & General Counsel
Comp: $825k
Ms. Jean M. Davis (Age 52)
Chief Information Officer
Comp: $258.78k
Mr. David Innes
Vice President of Investor Relations
Mr. Pankaj R. Shah C.A.
CPA, Financial Controller

Key Competitors

View All Competitors

NWBO Stock Analysis - Frequently Asked Questions

How have NWBO shares performed in 2024?: Northwest Biotherapeutics' stock was trading at $0.7010 at the beginning of the year. Since then, NWBO stock has decreased by 31.5% and is now trading at $0.48.
View the best growth stocks for 2024 here.
When is Northwest Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our NWBO earnings forecast.
How were Northwest Biotherapeutics' earnings last quarter?: Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) announced its earnings results on Tuesday, March, 5th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $0.45 million for the quarter.

What other stocks do shareholders of Northwest Biotherapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), (ZLTQ) (ZLTQ), Avid Bioservices (CDMO), Idera Pharmaceuticals (IDRA), Amarin (AMRN), Inovio Pharmaceuticals (INO) and MEI Pharma (MEIP).
How do I buy shares of Northwest Biotherapeutics?: Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:NWBO) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial